Thermogelling Hydroxypropyl Methylcellulose Nanoemulsions as Templates to Formulate Poorly Water-Soluble Drugs into Oral Thin Films Containing Drug Nanoparticles
Source abstract
Abstract
Oral thin films are an emerging solid dosage form for the delivery of poorly water-soluble drugs. Typical thin film formulations require nanomilling of drugs to improve their poor water solubility, followed by incorporating the drug nanoparticles in a polymer solution for casting. However, these formulations are not only inefficient and multistep but also limited to moderate drug loading capacity and susceptible to irreversible nanoparticle aggregation. Based on a widely used film-forming polymer, hydroxypropyl methylcellulose (HPMC), we developed thermogelling nanoemulsions with drug-loaded oil nanodroplets dispersed in a HPMC-loaded water phase. The nanoemulsions can directly act as film precursors for casting and provide robust templates to formulate oral films with uniform drug nanoparticles embedded in a dried HPMC matrix. The thermally gelled network effectively immobilizes the oil nanodroplets for confined nanoparticle crystallization and avoids potential irreversible nanoparticle aggregation, which enables high drug loading contents up to 63 wt %. The oral films also possess a tunable immediate release because the films have large surface-to-volume ratios and the drug nanoparticles are fast-dissolving. Overall, the thermogelling nanoemulsions show great promise for a more efficient and effective process to formulate HPMC and poorly water-soluble drugs into highly potent oral films with tunable immediate release.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Advanced Drug Delivery Systems · Hydrogels: synthesis, properties, applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
Campus for Research Excellence and Technological Enterprise, 138602 Singapore, Singapore
Funding
NSF grant
References (78)
Show source-provided references
1. 10.1111/j.2042-7158.2010.01030.x10.1111/j.2042-7158.2010.01030.x ↗
2. 10.1016/j.addr.2007.05.00310.1016/j.addr.2007.05.003 ↗
3. 10.2147/IJN.S59510.2147/IJN.S595 ↗
4. 10.1016/j.ajps.2014.08.00510.1016/j.ajps.2014.08.005 ↗
5. 10.1016/j.addr.2011.02.00110.1016/j.addr.2011.02.001 ↗
6. 10.1016/j.jconrel.2015.03.00610.1016/j.jconrel.2015.03.006 ↗
7. 10.1007/s11095-017-2284-210.1007/s11095-017-2284-2 ↗
8. 10.1007/s00228-012-1417-010.1007/s00228-012-1417-0 ↗
9. 10.1016/j.jconrel.2009.06.01410.1016/j.jconrel.2009.06.014 ↗
10. 10.1016/j.ajps.2016.05.00410.1016/j.ajps.2016.05.004 ↗
11. 10.1007/s12247-015-9237-210.1007/s12247-015-9237-2 ↗
12. 10.1016/j.xphs.2018.04.00610.1016/j.xphs.2018.04.006 ↗
13. 10.1016/j.ijpharm.2017.11.04010.1016/j.ijpharm.2017.11.040 ↗
14. 10.1016/j.ijpharm.2011.12.00110.1016/j.ijpharm.2011.12.001 ↗
15. 10.1016/j.ijpharm.2015.04.03410.1016/j.ijpharm.2015.04.034 ↗
16. 10.1016/j.ijpharm.2014.08.05110.1016/j.ijpharm.2014.08.051 ↗
17. 10.3390/bioengineering501001610.3390/bioengineering5010016 ↗
18. 10.1016/S0928-0987(02)00251-810.1016/S0928-0987(02)00251-8 ↗
19. 10.3390/pharmaceutics1003008610.3390/pharmaceutics10030086 ↗
20. 10.1016/j.ajps.2014.12.00610.1016/j.ajps.2014.12.006 ↗
21. 10.1002/jps.2469410.1002/jps.24694 ↗
22. 10.1016/j.ejpb.2012.01.00510.1016/j.ejpb.2012.01.005 ↗
23. 10.1016/j.ces.2015.03.02010.1016/j.ces.2015.03.020 ↗
24. 10.1016/j.ijpharm.2017.03.02310.1016/j.ijpharm.2017.03.023 ↗
25. 10.1002/jps.2043710.1002/jps.20437 ↗
26. 10.3390/membranes1012037610.3390/membranes10120376 ↗
27. 10.1002/jps.2224210.1002/jps.22242 ↗
28. 10.3390/pharmaceutics1312216210.3390/pharmaceutics13122162 ↗
29. 10.3109/03639045.2014.89295710.3109/03639045.2014.892957 ↗
30. 10.4103/1735-5362.23515610.4103/1735-5362.235156 ↗
31. 10.1021/js980403l10.1021/js980403l ↗
32. 10.1007/s11094-019-02017-910.1007/s11094-019-02017-9 ↗
33. 10.1038/s43016-019-0009-x10.1038/s43016-019-0009-x ↗
34. 10.1211/002235705595710.1211/0022357055957 ↗
35. 10.1016/j.colsurfb.2013.06.03410.1016/j.colsurfb.2013.06.034 ↗
36. 10.1016/j.ijpharm.2016.07.05810.1016/j.ijpharm.2016.07.058 ↗
37. 10.1111/ics.1210410.1111/ics.12104 ↗
38. 10.1016/S0939-6411(00)00069-210.1016/S0939-6411(00)00069-2 ↗
39. 10.3390/ma410186110.3390/ma4101861 ↗
40. 10.1016/j.ijpharm.2019.11884510.1016/j.ijpharm.2019.118845 ↗
41. 10.1016/j.ejpb.2007.05.01010.1016/j.ejpb.2007.05.010 ↗
42. 10.1089/ten.teb.2020.020210.1089/ten.teb.2020.0202 ↗
43. 10.1016/0144-8617(93)90137-S10.1016/0144-8617(93)90137-S ↗
44. 10.1002/app.1979.07024042010.1002/app.1979.070240420 ↗
45. 10.1007/s10570-018-02225-810.1007/s10570-018-02225-8 ↗
46. 10.3390/polym705077710.3390/polym7050777 ↗
47. 10.1002/advs.20200167710.1002/advs.202001677 ↗
48. 10.1039/c5sm02958a10.1039/c5sm02958a ↗
49. 10.1021/jp071295710.1021/jp0712957 ↗
50. 10.1039/c5sm02051d10.1039/c5sm02051d ↗
51. 10.1021/acs.chemmater.9b0424110.1021/acs.chemmater.9b04241 ↗
52. 10.1021/acs.cgd.5b0095610.1021/acs.cgd.5b00956 ↗
53. 10.1002/adma.20200861810.1002/adma.202008618 ↗
54. 10.1063/1.45924010.1063/1.459240 ↗
55. 10.1039/c5ce01148e10.1039/c5ce01148e ↗
56. 10.1002/smll.20180337210.1002/smll.201803372 ↗
57. 10.1016/j.ejpb.2008.05.03010.1016/j.ejpb.2008.05.030 ↗
58. 10.1039/c6ra28150h10.1039/c6ra28150h ↗
59. 10.1002/adfm.20150127410.1002/adfm.201501274 ↗
60. 10.1021/jacs.5b0911110.1021/jacs.5b09111 ↗
61. 10.1016/j.ajps.2017.07.01010.1016/j.ajps.2017.07.010 ↗
62. 10.1016/j.ijpharm.2011.08.03210.1016/j.ijpharm.2011.08.032 ↗
63. U.S. Food and Drug Administration – Dissolution Methods Database https://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_getalldata.cfm(accessed 2022-05-12)
64. 10.1021/acs.molpharmaceut.7b0035410.1021/acs.molpharmaceut.7b00354 ↗
65. 10.1023/A:101621280428810.1023/A:1016212804288 ↗
66. 10.1208/pt07023310.1208/pt070233 ↗
67. 10.1016/j.ejpb.2013.12.01910.1016/j.ejpb.2013.12.019 ↗
68. 10.1081/DDC-12000300710.1081/DDC-120003007 ↗
69. 10.1016/j.ijpharm.2015.04.06910.1016/j.ijpharm.2015.04.069 ↗
70. 10.1016/j.ejps.2008.06.00910.1016/j.ejps.2008.06.009 ↗
71. 10.1016/j.ijpharm.2011.04.03410.1016/j.ijpharm.2011.04.034 ↗
72. 10.1016/0168-3659(87)90035-610.1016/0168-3659(87)90035-6 ↗
73. 10.31838/ijprt/08.01.0210.31838/ijprt/08.01.02 ↗
74. Hopfenberg, H. B. Controlled Release from Erodible Slabs, Cylinders, and Spheres. In ACS Symposium Series, 1976; Vol. 33, pp. 26–32.10.1021/bk-1976-0033.ch003 ↗
75. 10.1016/j.ejps.2018.02.02910.1016/j.ejps.2018.02.029 ↗
76. 10.1021/cg401298210.1021/cg4012982 ↗
77. 10.1016/j.drudis.2007.11.00610.1016/j.drudis.2007.11.006 ↗
78. 10.1021/cg501222n10.1021/cg501222n ↗